CVS wants to become a medical powerhouse. Will long lines and understaffing hold it back?; Listen: The plight of the VC, Gilead’s latest setback, & more M&A

Taking stock of the drug industry, from the lab to the medicine chest

January 26, 2024 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Suzanne Kreiter/Globe staff STAT+ | CVS wants to become a medical powerhouse. Will long lines and understaffing hold it back? CVS's goal is to consolidate the fragmented U.S. health care system into a highly profitable business. But hurdles lie ahead. By Thomas Lee — Boston Globe Listen: The plight of the VC, Gilead's latest setback, & more M&A In this episode of "The Readout LOUD," we take a look at Gilead Sciences' struggle to turn itself into an oncology company. By Damian Garde and Allison DeAngelis and Adam Feuerstein STAT+ | Vaccines save lives and generate profits. Why is investment lagging? The report from industry group BIO cited a variety of factors in the underfunding of vaccines, including limited return on investment. By Jonathan Saltzman — Boston Globe Alex Hogan/STAT STAT+ | Up and down the ladder: The latest comings and goings From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry. By Ed Silverman

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser